Overview

• The Transform trial aims to revolutionize prostate cancer screening by testing combinations of PSA tests, genetic testing, and high-speed MRI scans.
• Initial phase to involve 12,500 men, with results expected in three years; subsequent phase to include up to 300,000 participants.
• Researchers focus on reducing prostate cancer deaths and the harm caused by outdated screening methods.
• Significant emphasis on including diverse populations, with at least one in ten participants being black men, who are at higher risk.
• The trial could set new global standards for prostate cancer screening, potentially saving tens of thousands of lives annually.